- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Clinical Trials
- June 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- May 2024
- 134 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- November 2024
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- May 2024
- 160 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- April 2023
- 224 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- April 2023
- 112 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- July 2018
- 50 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- January 2024
- 110 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2022
- 114 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 216 Pages
Global
From €2377EUR$2,500USD£1,997GBP
The Acute Ischemic Stroke Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat acute ischemic stroke, a type of stroke caused by a blockage in a blood vessel supplying the brain. These drugs are used to reduce the risk of disability and death from stroke, and to improve the patient's quality of life. Commonly used drugs include thrombolytics, anticoagulants, antiplatelet agents, and neuroprotectants.
The Acute Ischemic Stroke Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Novartis, and Boehringer Ingelheim. Show Less Read more
